Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 9370
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
TDS Pharm Co. Ltd. engages in the development and manufacture of transdermal drug delivery systems. Its products include cataplasma, plasta, fucidin band, and prescription drugs. The company was founded on November 11, 2002 and is headquartered in Seongnam-si, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBI
Data is available to registered users only
Buy
Sell